PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE

The study aimed to develop a personalized pharmacological correction of immune, metabolic and neuropsychiatric disorders in chronic cerebral ischemia (CCI) stages I and II. The study included 104 patients, of which 76 were female and 28 were male, with CCI on the background of grade II hypertension,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. I. Konoplya, A. A. Shulginova, N. A. Bystrova, V. P. Gavrilyuk, G. N. Ryzhikova
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	chronic cerebral ischemia personalized pharmacological correction of immunometabolic disorders Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/fff6df38d96e4e6fb50d431519ec5c22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fff6df38d96e4e6fb50d431519ec5c22
record_format	dspace
spelling	oai:doaj.org-article:fff6df38d96e4e6fb50d431519ec5c222021-11-18T08:03:51ZPERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE1563-06252313-741X10.15789/1563-0625-PPC-1988https://doaj.org/article/fff6df38d96e4e6fb50d431519ec5c222021-10-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1988https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe study aimed to develop a personalized pharmacological correction of immune, metabolic and neuropsychiatric disorders in chronic cerebral ischemia (CCI) stages I and II. The study included 104 patients, of which 76 were female and 28 were male, with CCI on the background of grade II hypertension, of which 52 patients were with stage I and 52 with stage II at the age of 50±5 years. Clinical and laboratory parameters were studied in 22 healthy donors of the same age who formed a control group. Patients with CCI were randomized according to gender, age, treatment method, concomitant pathology, and duration of the disease. Evaluation of clinical and laboratory data was carried out at the beginning of treatment and 2 weeks after its end. The sorption capacity of erythrocytes and the sorption capacity of the glycocalyx (SEG), the activity of lipid peroxidation processes, the state of the antioxidant system were determined in blood plasma and erythrocytes, the level of stable metabolites of nitric oxide (SMNO), neopterin, C-reactive protein, cytokines (TNFα, IL-1β, IL-8, IFNγ, IL-18, G-CSF, IL-4, IL-10), immunoglobulins (IgM, IgG, IgA), complement system components (C3, C4, C5, C5A), phagocytic and oxygen-dependent activity of polymorphonuclear blood leukocytes. It has been established that for patients with CCI I with high concentrations of IL-8, IL-10, SMNO and a low SEG index, the intake of Cereton and Actovegin or Ceraxon and Mexicor will be insufficient for effective correction of immunometabolic disorders, which requires additional administration of an immunomodulator. Patients with CCI II, who have a higher plasma level of TNFα, IL-10 and low SEG values, need to prescribe Ceraxon, Mexicor and Glutoxim or Ceraxon, Mexicor and Polyoxidonium in order to obtain the maximum clinical and laboratory positive effect.A. I. KonoplyaA. A. ShulginovaN. A. BystrovaV. P. GavrilyukG. N. RyzhikovaSPb RAACIarticlechronic cerebral ischemiapersonalized pharmacological correction of immunometabolic disordersImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 4, Pp 957-962 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	chronic cerebral ischemia personalized pharmacological correction of immunometabolic disorders Immunologic diseases. Allergy RC581-607
spellingShingle	chronic cerebral ischemia personalized pharmacological correction of immunometabolic disorders Immunologic diseases. Allergy RC581-607 A. I. Konoplya A. A. Shulginova N. A. Bystrova V. P. Gavrilyuk G. N. Ryzhikova PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
description	The study aimed to develop a personalized pharmacological correction of immune, metabolic and neuropsychiatric disorders in chronic cerebral ischemia (CCI) stages I and II. The study included 104 patients, of which 76 were female and 28 were male, with CCI on the background of grade II hypertension, of which 52 patients were with stage I and 52 with stage II at the age of 50±5 years. Clinical and laboratory parameters were studied in 22 healthy donors of the same age who formed a control group. Patients with CCI were randomized according to gender, age, treatment method, concomitant pathology, and duration of the disease. Evaluation of clinical and laboratory data was carried out at the beginning of treatment and 2 weeks after its end. The sorption capacity of erythrocytes and the sorption capacity of the glycocalyx (SEG), the activity of lipid peroxidation processes, the state of the antioxidant system were determined in blood plasma and erythrocytes, the level of stable metabolites of nitric oxide (SMNO), neopterin, C-reactive protein, cytokines (TNFα, IL-1β, IL-8, IFNγ, IL-18, G-CSF, IL-4, IL-10), immunoglobulins (IgM, IgG, IgA), complement system components (C3, C4, C5, C5A), phagocytic and oxygen-dependent activity of polymorphonuclear blood leukocytes. It has been established that for patients with CCI I with high concentrations of IL-8, IL-10, SMNO and a low SEG index, the intake of Cereton and Actovegin or Ceraxon and Mexicor will be insufficient for effective correction of immunometabolic disorders, which requires additional administration of an immunomodulator. Patients with CCI II, who have a higher plasma level of TNFα, IL-10 and low SEG values, need to prescribe Ceraxon, Mexicor and Glutoxim or Ceraxon, Mexicor and Polyoxidonium in order to obtain the maximum clinical and laboratory positive effect.
format	article
author	A. I. Konoplya A. A. Shulginova N. A. Bystrova V. P. Gavrilyuk G. N. Ryzhikova
author_facet	A. I. Konoplya A. A. Shulginova N. A. Bystrova V. P. Gavrilyuk G. N. Ryzhikova
author_sort	A. I. Konoplya
title	PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
title_short	PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
title_full	PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
title_fullStr	PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
title_full_unstemmed	PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE
title_sort	personalized pharmacological correction of immune systems, metabolic and neuropsychic parameters in chronic brain ischemia of stage i and ii on the background of hypertension disease
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/fff6df38d96e4e6fb50d431519ec5c22
work_keys_str_mv	AT aikonoplya personalizedpharmacologicalcorrectionofimmunesystemsmetabolicandneuropsychicparametersinchronicbrainischemiaofstageiandiionthebackgroundofhypertensiondisease AT aashulginova personalizedpharmacologicalcorrectionofimmunesystemsmetabolicandneuropsychicparametersinchronicbrainischemiaofstageiandiionthebackgroundofhypertensiondisease AT nabystrova personalizedpharmacologicalcorrectionofimmunesystemsmetabolicandneuropsychicparametersinchronicbrainischemiaofstageiandiionthebackgroundofhypertensiondisease AT vpgavrilyuk personalizedpharmacologicalcorrectionofimmunesystemsmetabolicandneuropsychicparametersinchronicbrainischemiaofstageiandiionthebackgroundofhypertensiondisease AT gnryzhikova personalizedpharmacologicalcorrectionofimmunesystemsmetabolicandneuropsychicparametersinchronicbrainischemiaofstageiandiionthebackgroundofhypertensiondisease
_version_	1718422330691026944

PERSONALIZED PHARMACOLOGICAL CORRECTION OF IMMUNE SYSTEMS, METABOLIC AND NEUROPSYCHIC PARAMETERS IN CHRONIC BRAIN ISCHEMIA OF STAGE I AND II ON THE BACKGROUND OF HYPERTENSION DISEASE

Ejemplares similares